NCT04538599View on ClinicalTrials.gov

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

February 17, 2021

Study Completion Date

November 30, 2021

Conditions
Hematologic Malignancies
Interventions
DRUG

RD13-01 cell infusion

Universal CAR-T cells targeting CD7

Trial Locations (1)

310003

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

He Huang

OTHER

NCT04538599 - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies | Biotech Hunter | Biotech Hunter